Debu Tripathy, MD, MD Anderson Cancer Center

Articles by Debu Tripathy, MD, MD Anderson Cancer Center

Updated Data for Metastatic HER2+ Breast Cancer

ByRuth O'Regan, MD, University of Rochester Medical Center,Joyce O'Shaugnessy, MD, Texas Oncology,Hope S. Rugo, MD, FASCO, UCSF Helen Diller Family Comprehensive Cancer Center,Debu Tripathy, MD, MD Anderson Cancer Center

January 25th 2021

Prognostic Tools for Early-Stage HER2+ Breast Cancer

ByRuth O'Regan, MD, University of Rochester Medical Center,Joyce O'Shaugnessy, MD, Texas Oncology,Hope S. Rugo, MD, FASCO, UCSF Helen Diller Family Comprehensive Cancer Center,Debu Tripathy, MD, MD Anderson Cancer Center

January 25th 2021

Current Treatment Landscape for HER2+ Breast Cancer

ByRuth O'Regan, MD, University of Rochester Medical Center,Joyce O'Shaugnessy, MD, Texas Oncology,Hope S. Rugo, MD, FASCO, UCSF Helen Diller Family Comprehensive Cancer Center,Debu Tripathy, MD, MD Anderson Cancer Center

January 25th 2021

Latest Updated Articles

Prognostic Tools for Early-Stage HER2+ Breast Cancer
January 25th 2021
Current Treatment Landscape for HER2+ Breast Cancer
January 25th 2021
Updated Data for Metastatic HER2+ Breast Cancer
January 25th 2021

Trending on OncLive

INBRX-106 Plus Pembrolizumab Improves Responses and PFS in First-Line PD-L1–Positive HNSCC

FDA Approves Pirtobrutinib for Previously Untreated CLL/SLL

‘Our Impact Will Be Broad and Transformative’: Wells Messersmith, MD, Takes the Reins at CU Anschutz Cancer Center

AUA Releases Guideline Amendment for NMIBC

Five Under 5: Top Oncology Videos for the Week of 9/27